Tap to start →
Photo: Vitaly Gariev / Unsplash
1 / 3
Survodutide is an investigational weekly injection from Boehringer Ingelheim and Zealand Pharma that activates both the glucagon and GLP-1 receptors.
2 / 3
Survodutide is a dual agonist of the glucagon and GLP-1 receptors.
3 / 3
Survodutide tests whether adding glucagon to GLP-1 helps weight and liver health, a question that shapes several pipeline drugs.
Survodutide is an investigational weekly injection from Boehringer Ingelheim and Zealand Pharma that activates both the glucagon and GLP-1 receptors.
Tap below for the full page. Not medical advice; talk to your clinician about your care.